Article | April 02, 2026
Article | March 24, 2026
OPDP’s 2026 Untitled Letters: Early Enforcement Trends in Prescription Drug Promotion
Read More
Article | March 19, 2026
Enforcement Discretion for “No Artificial Colors” Food Labeling Claims
Read More
Article | February 23, 2026
Prepare for Impact: CCPA Risk Assessment Regulations Now in Effect
Read More
Article | February 18, 2026
A Recent Challenge to FDA’s Approach to Dietary Supplements Claims
Read More
Article | February 17, 2026
Sunshine Reporting Season Has Begun: Are You Meeting the Requirements?
Read More
Article | February 10, 2026
San Francisco’s Ultra-Processed Foods Lawsuit Signals a New Enforcement Frontier
Read More
Article | February 05, 2026
Navigating FDA Promotional Compliance: TEVIMBRA and Digital Brand Assets
Read More
Article | January 27, 2026
Privacy and AI Heatmap for 2026: What Device & Drug Makers Should Watch in 2026
Read More
Article | January 15, 2026
What FDA’s TEMPO Pilot and CMS’s ACCESS Model Mean for Medical Device Manufacturers
Read More
Article | January 08, 2026
Clarity in Complexity: The Benefits of a Business Stance Playbook
Read More